Physician demand could wind up being a determining factor in whether the reimbursement outlook for Amgen Inc.'s Repatha (evolocumab) improves following the long-awaited release of cardiovascular outcomes data for the PCSK9 inhibitor.
While the overall positive results of Amgen's FOURIER trial were announced last month, the level of benefit was unveiled March...







